## Management of Steroid-Resistant Minimal Change Disease ### Definition and Epidemiology **Steroid-resistant MCD (SR-MCD):** Failure to achieve remission (proteinuria <0.3 g/day) after 4 weeks of high-dose corticosteroids (1 mg/kg/day prednisone or equivalent). - Occurs in ~10% of adult MCD cases - Associated with worse renal outcomes if untreated - Requires escalation to second-line agents ### Why Tacrolimus is First-Line for SR-MCD **Key Point:** Tacrolimus (a calcineurin inhibitor) is the evidence-based drug of choice for steroid-resistant MCD, with remission rates of 60–80% in prospective trials. #### Mechanism of Action 1. Inhibits calcineurin → blocks IL-2 and TNF-α production 2. Suppresses T cell activation and podocyte dysfunction 3. Stabilizes the actin cytoskeleton of podocytes 4. Restores the glomerular filtration barrier integrity #### Dosing and Monitoring - **Initial dose:** 0.05–0.1 mg/kg/day (divided into two doses) - **Target trough level:** 5–15 ng/mL (therapeutic drug monitoring essential) - **Duration:** Minimum 3 months for response assessment - **Monitoring:** Serum creatinine, potassium, magnesium, glucose (monthly initially) **High-Yield:** Tacrolimus achieves remission in 60–80% of SR-MCD cases within 3–6 months, making it the preferred second-line agent before considering cyclophosphamide. #### Advantages Over Cyclophosphamide in SR-MCD - Lower toxicity profile (no hemorrhagic cystitis or infertility risk) - Reversible mechanism (can discontinue if side effects occur) - Effective even in patients with prior cyclophosphamide exposure - Allows concurrent low-dose corticosteroid continuation **Clinical Pearl:** Tacrolimus is preferred over cyclophosphamide in SR-MCD because MCD is a T cell–mediated disease, and calcineurin inhibitors directly target the pathogenic T cell dysfunction. Cyclophosphamide is reserved for tacrolimus-resistant or intolerant cases. ### Treatment Algorithm for SR-MCD ```mermaid flowchart TD A[Minimal Change Disease]:::outcome --> B[High-dose corticosteroids<br/>1 mg/kg/day × 4 weeks]:::action B --> C{Remission achieved?}:::decision C -->|Yes| D[Taper corticosteroids<br/>Maintenance therapy]:::action C -->|No| E[Steroid-Resistant MCD]:::outcome E --> F[Tacrolimus 0.05-0.1 mg/kg/day]:::action F --> G{Response at 3-6 months?}:::decision G -->|Yes| H[Continue tacrolimus<br/>Taper corticosteroids]:::action G -->|No| I[Tacrolimus-resistant:<br/>Consider cyclophosphamide]:::urgent ``` ### Relapse Management If relapse occurs during or after tacrolimus taper: - Reinitiate tacrolimus at previous effective dose - Long-term maintenance (1–2 years) reduces relapse risk - Gradual taper over 6–12 months when stable [cite:Harrison 21e Ch 279; Kidney Disease: Improving Global Outcomes (KDIGO) 2021 Clinical Practice Guideline for Glomerulonephritis]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.